Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.18 USD

53.18
3,871,981

+1.98 (3.87%)

Updated Jul 25, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

by Kinjel Shah

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs

by Zacks Equity Research

FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources

Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

by Zacks Equity Research

Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

Mark Vickery headshot

Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), Novo Nordisk (NVO) and NVIDIA (NVDA).

Alphabet Halts Glucose Lens Work to Focus on Other Projects

by Zacks Equity Research

Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.

Regeneron (REGN) Rides on Eylea and Dupixent's Performance

by Zacks Equity Research

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

by Zacks Equity Research

With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

by Zacks Equity Research

Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug

by Zacks Equity Research

Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.

Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.

Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.

Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

by Zacks Equity Research

We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

by Zacks Equity Research

Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.

Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates

by Zacks Equity Research

Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.

BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.

Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod

by Zacks Equity Research

Earnings releases and key data-read outs were the key developments in the biotech sector last week.

Novo Nordisk (NVO) Faces Pricing Pressure and Competition

by Zacks Equity Research

Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.

    Regeneron's Dupixent Meets Goals in Nasal Polyps Studies

    by Zacks Equity Research

    Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.

      Emergent Completes Acquisition of Narcan Maker Adapt Pharma

      by Zacks Equity Research

      Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.

        3 Large-Cap Pharma Stocks Performing Better Than Industry

        by Zacks Equity Research

        We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

        Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

        by Zacks Equity Research

        Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.